Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
symbols : TAK crawled time : 13:30 save search
Takeda Announces Positive Topline Results from Phase 2 Study Evaluating Mezagitamab (TAK-079), a Potential Best-in-Class Anti-CD38 Monoclonal Antibody, for Primary Immune Thrombocytopenia
Published: 2024-03-13 (Crawled : 13:30) - biospace.com/
TAK | $13.23 0.38% 0.0% 2.3M
|
Health Technology
|
| O: 0.21%
H: 0.17%
C: 0.14%
tak-079 positive topline potential results study
Chiesi Group and Oak Hill Bio announce License and Development Agreement to develop, manufacture, and commercialize OHB-607, a potentially transformative neonatal therapy
Published: 2024-01-09 (Crawled : 13:30) - biospace.com/
TAK | $13.23 0.38% 0.0% 2.3M
|
Health Technology
|
| O: -0.27%
H: 0.61%
C: -0.2%
ohb-607 license group oak agreement therapy
Takeda Announces FDA Acceptance of BLA for Subcutaneous Administration of ENTYVIO® (vedolizumab) for Maintenance Therapy in Moderately to Severely Active Crohn’s Disease
Published: 2023-09-13 (Crawled : 13:30) - biospace.com/
TAK | $13.23 0.38% 0.0% 2.3M
|
Health Technology
|
| O: 0.63%
H: 0.5%
C: 0.31%
entyvio fda disease active therapy
Arcturus Therapeutics Reports New Data Demonstrating Neutralizing Antibody Immune Response to the SARS-CoV-2 Omicron Variant from ARCT-154 and ARCT-165 Booster Clinical Trial
Published: 2022-01-25 (Crawled : 13:30) - biospace.com/
TAK | $13.23 0.38% 0.0% 2.3M
|
Health Technology
|
| O: -0.76%
H: 2.02%
C: 1.04%
JNJ | $144.45 -2.13% 0.03% 13M
|
Health Technology
|
| O: -0.37%
H: 3.73%
C: 3.25%
ARCT 4 | $30.15 2.87% 2.79% 390K
|
Health Technology
|
| O: 0.24%
H: 4.13%
C: 1.44%
arct-154 trial therapeutics response sars-cov-2 report pons antibody
Arcturus Therapeutics Appoints Jing Marantz, M.D., Ph.D., M.B.A. to its Board of Directors
Published: 2021-12-13 (Crawled : 13:30) - biospace.com/
TAK | $13.23 0.38% 0.0% 2.3M
|
Health Technology
|
| O: -0.59%
H: 0.0%
C: 0.0%
JNJ | $144.45 -2.13% 0.03% 13M
|
Health Technology
|
| O: -0.41%
H: 0.0%
C: 0.0%
KRYS | $170.08 0.19% 0.19% 200K
|
Health Technology
|
| O: -1.65%
H: 0.0%
C: 0.0%
ARCT 4 | $30.15 2.87% 2.79% 390K
|
Health Technology
|
| O: -6.92%
H: 0.0%
C: 0.0%
therapeutics
Takeda Unveils New Research to Advance Patient Care in Hematology and Oncology at 63rd American Society of Hematology (ASH) Annual Meeting
Published: 2021-12-07 (Crawled : 13:30) - biospace.com/
TAK | $13.23 0.38% 0.0% 2.3M
|
Health Technology
|
| O: 1.55%
H: 0.0%
C: 0.0%
ema research
Arcturus Therapeutics to Participate in Piper Sandler 33rd Annual Healthcare Conference
Published: 2021-11-22 (Crawled : 13:30) - biospace.com/
TAK | $13.23 0.38% 0.0% 2.3M
|
Health Technology
|
| O: -1.03%
H: 0.14%
C: -0.65%
JNJ | $144.45 -2.13% 0.03% 13M
|
Health Technology
|
| O: -1.22%
H: 1.0%
C: -0.83%
ARCT 4 | $30.15 2.87% 2.79% 390K
|
Health Technology
|
| O: -2.88%
H: 1.38%
C: -1.52%
conference therapeutics
Gainers vs Losers
| 58% | 42% |
Top 10 Gainers
WISA 4 | $6.06 246.29% 71.12% 200M
|
Electronic Technology
VIAO | $0.265 -13.96% 35.85% 960K
|
Electronic Technology
JAGX | $0.178 49.83% 33.26% 600M
|
Health Technology
SXTC | $1.68 43.59% 30.36% 34M
|
Health Technology
DYNT | $0.531 43.36% 30.24% 22M
|
Health Technology
KA | $0.4796 41.06% 29.11% 5.3M
|
Manufacturing
PALI | $5.86 40.87% 29.01% 29M
|
Manufacturing
CLNN | $0.319 -3.74% 28.75% 6.3M
|
BSGM | $1.52 38.18% 27.63% 3.3M
|
Health Technology
MCBC | $13.67 37.66% 27.36% 2.2M
|
Finance
Your saved searches
Save your searches and get alerts when important news are released.